ERCC1、RRM1和TUBB3指导个体化化疗方案治疗晚期非小细胞肺癌的评价被引量：4

Evaluation of individualized chemotherapy for advanced non-small cell lung cancer guided by ERCC1,RRM1 and TUBB3

下载PDF

导出

摘要目的:探讨切除修复交叉互补基因1(excision repair cross complement group1,ERCC1)、核糖核苷酸还原酶M1亚基(ri-bonucleotide reduc tase,RRM1)、3型β微管蛋白(tubulin beta-3,TUBB3)指导化疗药物个休化选择在晚期非小细胞肺癌(non-mall cell lung cancer,NSCLC)患者的疗效和安全性。方法:47例晚期NSCLC患者,按病理组织充足与否分个体化化疗治疗组(A组)及对照组(B组)。A组采用分支DNA-液相芯片技术测定ERCC1、RRM1及TUBB3的mRNA水平,并根据测定结果确定化疗方案,B组则使用吉西他滨+顺铂治疗。结果:A组有效率为63.2%,明显高于B组(P<0.05);A组、B组疾病控制率分别为78.9%和50.0%(P<0.05);A组中吉西他滨+顺铂患者的有效率高于B组相同方案化疗者;2组生活质量均较治疗前明显提高(P<0.05),但2组改善率无显著差别(P>0.05);2组不良反应无差异且均易耐受。结论:分支DNA-液相芯片技术测定ERCC1、RRM1及TUBB3的mRNA水平用于指导晚期NSCLC个体化化疗方案,能显著提高化疗有效率;吉西他滨+顺铂方案在分子标志物指导策略下运用效果更明显,但仍需进一步探索更有效的个体化治疗方案。 Objective ：To explore the efficacy and safety of individualized selection of chemotherapy drug guided by excision repair cross complement groupl（ERCC1）,ribonucleotide reduc tase 1 （RRM1） and tubulin beta 3（TUBB3） in patients with advanced non- small cell lung cancer（NSCLC）. Methods：Totally 47 cases of advanced NSCLC were divided into individualized chemotherapy treat- ment group （group A） and control group （group B） according to hi stopathological tissue sufficient or not. In group A, mRNA levels of ERCC1 ,RRM1 and TUBB3 were measured by branched DNA-liquid chip technique and chemotherapy regimen was formulated ac- cording to the measured results. Group B were treated by gemcitabine plus cisplatin. Results：Effective rate of group A was 63.2%, significantly higher than that of group B（P〈0.05）. Disease control rates of group A and group B were 78.9% and 50.0% respectively （P〈0.05）. Effective rate was significantly higher in patients treated by gemcitabine plus cisplatin in group A than in patients received the same treatment in group B. Quality of life in both groups was improved significantly after treatment（P〈0.05） than before treat- ment, but there was no significant difference in improvement rate （P 〉0.05）. There was no difference in adverse reactions between both groups and all patients were well tolerated. Conclusions：Determination of mRNA levels of ERCC1, RRM1 and TUBB3 by branched DNA-liquid chip technique can guide individualized chemotherapy for advanced NSCLC and significantly improve chemotherapy efficiency; however,further exploration of more effective individualized treatment plan is needed.

作者柯红崔洁王小松聂成钢王雪梅罗备涂睿

机构地区葛洲坝中心医院三峡大学第三临床医学院肿瘤科

出处《重庆医科大学学报》 CAS CSCD 北大核心 2013年第5期502-505,共4页 Journal of Chongqing Medical University

关键词非小细胞肺癌晚期切除修复交叉互补基因1 核糖核苷酸还原酶M1亚基 3型β微管蛋白个体化方案分支DNA-液相芯片 non-small cell lung cancer advanced period excision repair cross complement group 1 ribonucleotide reduc tase l tubulin beta 3 individualized chemotherapy regimens branched DNA-liquid chip

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献8

1Paredes L A,Blanco G C,Elizondo E M,et al.Expression of pro teins associated with multidrug resistance and resistance to chemothera1 py in lung cancer[J]. Arch Bronconeumol,2007,43(9):479-484.
2周彩存,徐崇锐.原位RRM1和ERCC1蛋白表达水平预测吉西他滨为基础化疗方案对非小细胞肺癌的疗效[J].循证医学,2010,10(1):26-27. 被引量：3
3陈芹,周彩存,张颉.ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义[J].肿瘤,2007,27(9):719-722. 被引量：57
4Azuma K,Sasada T,Kawahara A,et al.Expression of ERCC1 and class m beta-tubulin in non-small cell lung cancer patients treated with earboplatin and paclitaxel[J].Lung Cancer,2009,64(3):326-333.
5Wang L,Wei J,Qian X,et al.ERCC1 and BRCA1 mRNA expres- sion levels in metastatic malignant effusions is associated with chem- osensitivity to eisplatin and/or doeetaxel[J].BMC Cancer, 2008,8 : 97.
6Rosell R,Danenberg K D,Alberola V,et al.Ribonueleotide redue- tase messenger RNA expression and survival in gemcitabine/eisplatin- treated advanced non-small cell lung cancer patients[J].Clin Cancer Res, 2004,10(4) : 1318-1325.
7Zheng Z,Chen T,Li X,et al.DNA synthesis and repair genes RRM1 and ERCC1 in lung eaneer[J].N Engl J Meal,2007,356(8):800-808.
8冷雪峰,冼磊,陈铭伍,阳诺.非小细胞肺癌组织中ERCC1及TUBB3基因mRNA的表达及其临床意义[J].肿瘤预防与治疗,2012,25(1):1-5. 被引量：4

二级参考文献26

1Olaussen KA, Dunant A, Fouret P. et al. DNA repair by ERCC] in non-small-cell lung cancer and cisplatin-based adjuvant chemoI therapy[J]. N Engl J Med, 2006, 355(10) : 983-991.
2Hayashi Y, Kuriyama H, Umezu H, et al. Class III 13-tubulin ex- pression in tumor cells is con'elated with resistance to doeetaxel in patients with completely resected non-small cell lung cancer[ J]. lntem Med, 2009, 48(4) : 203-208.
3Chen W, Zhang S, Zou X. et al. Evaluation on the incidence, mortality and tendency of lung cancer in china[ J]. Thoracic Canc- er, 2010, 1(I): 35-40.
4Croteau D, Peng Y, Van B H. et al. DNA repair GETS physical: mapping an XPA-binding site on ERCC1 [ J]. DNA Repair, 2008, 7(5) .. 819-826.
5Friedberg EC. How nucleotide excision repair protects against cancer[J]. Nature Rev Cancer, 2001, 1(1) : 22-33.
6Azuma K, Komohara Y, Sasada T, et al. Excision repair cross- complementation group 1 predicts progression-free and overall sur-viral in non-small cell lung cancer patients treated with platinum- based chemotherapy[J]. Cancer Sci, 2007, 98(9) : 1336-1343.
7Hwang IG, Ahn MJ, Park BB, et al. ERCC1 expression as a prog- nostic marker in N2 ( + ) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy [J]. Cancer, 2008, 113(6): 1379-1386.
8Ota S, lshii G, Goto K. Immunohistochemieal expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non small-cell lung cancer treated with cisplatin-based chemotherapy [J]. Lung Cancer, 2009, 64(1): 89-104.
9Matakidou A, El Galta R, Webb EL, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer[ J]. Hum Mol Genet, 2007, 16 (19) : 2333-2340.
10Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene muta- tions[J]. J Clin Oncol, 1999, 17(6): 1756-1793.